Discrepancies between Nomenclature and Indications of Psychotropics

Fusaka Minami, Joseph Zohar, Takefumi Suzuki, Teruki Koizumi, Masaru Mimura, Gohei Yagi, Hiroyuki Uchida

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Introduction While the current nomenclature of psychotropic drugs is disease-based, their approved indications do not always match their classifications. Methods Information on approved indications of second-generation antipsychotics and newer antidepressants that are available in the United States (US), the United Kingdom (UK), France, Germany, and Japan were extracted from their packet inserts. Results A significant proportion of atypical antipsychotics were approved for psychiatric conditions other than psychotic disorders (i. e., bipolar disorder, major depressive disorder, and autistic disorder) as follows: 76.9% in the US, 66.7% in the UK, 66.7% in France, 60.0% in Germany, and 44.4% in Japan. Likewise, more than half of newer antidepressants had approved indications for psychiatric conditions other than depression (e. g., panic disorder, obsessive compulsive disorder, social anxiety disorder, general anxiety disorder, and post-traumatic stress disorder): 56.3% in the US, 69.2% in the UK, 69.2% in France, 50.0% in Germany, and 62.5% in Japan. Conclusions Our results raise concerns regarding generic terminologies of antipsychotics and antidepressants since the conventional indication-based nomenclature does not fit well with the official indication.

Original languageEnglish
Pages (from-to)175-179
Number of pages5
Issue number4
Publication statusPublished - 2019 May 23


  • NbN
  • antidepressant
  • antipsychotic
  • indication
  • neuroscience-based nomenclature

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Discrepancies between Nomenclature and Indications of Psychotropics'. Together they form a unique fingerprint.

Cite this